Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

65.66 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution
Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations — Opdivo... 
Via Benzinga
Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters
Bristol Myers Squibb Co (NYSE: BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments to shareholders of the... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... 
Via Benzinga
Bristol Myers' Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma
The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
Bristol-Myers Squibb Co Is Slipping, Watch This Bounce Level
Traders should watch for very strong support around the $60.00 area. This level is where the shares were defended in early March 2021. 
Via Talk Markets
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
I’d Have To Disagree With Buffett’s Latest Stock Sells (As He Sells, I Buy)
Warren Buffett oversees a common stock portfolio for Berkshire Hathaway worth almost $300 billion. This portfolio has largely been built by steadily accumulating shares in high-quality businesses over... 
Via Talk Markets
Bristol-Myers' Zeposia Scores FDA Approval For Ulcerative Colitis
The FDA has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
2 Top Dividend Stocks for a Better Retirement
They're safe companies that also regularly raise their payouts. 
Via The Motley Fool
Topics Retirement
Exposures Pension
Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies
Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
2 High-Yield Dividend Stocks for 2021
Why you might want to consider adding these two best-in-class stocks to your portfolio. 
Via The Motley Fool
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia
Bristol-Myers Squibb & Co (NYSE: BMY) released positive new data on its ulcerative colitis (UC) candidate Zeposia (ozanimod) at Digestive Disease Week (DDW),... 
Via Benzinga
Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal Cancer
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Bristol Myers Squibb & Co's (NYSE: BMY... 
Via Benzinga
Better Mood Day
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
Bristol Myers' Relatlimab/Opdivo Combo Therapy Tops Opdivo Alone in Untreated Melanoma Patients
Bristol Myers Squibb Co (NYSE: BMY) announced detailed results from the Phase 2/3 RELATIVITY-047 trial evaluating a fixed-dose combination of relatlimab and Opdivo... 
Via Benzinga
Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study
Heat Biologics Inc (NASDAQ: HTBX) has reported interim data from the Phase 1/2 trial evaluating its lead product, HS-110, in combination with ... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Exposures COVID-19
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings
I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG’s (OTC: RHHBY)... 
Via Benzinga
Exscientia, Bristol Myers Expand AI Based Drug Discovery Collaboration With Potential Milestones Over $1.2B
Privately-held Exscientia has expanded its collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY) that builds upon Exscientia's... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Why Agenus Stock Skyrocketed Today
The biotech announced a big licensing deal with Bristol Myers Squibb. 
Via The Motley Fool
Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors
Bristol-Myers Squibb Co (NYSE: BMY) and Agenus Inc (NASDAQ: AGEN) have entered into a global exclusive license agreement, under which Bristol Myers will... 
Via Benzinga
Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and... 
Via Benzinga
Cathie Wood Cuts Apple Stake Almost Entirely — And Buys More Coinbase
Cathie Wood-led Ark Investment Management on Monday shed nearly all of its stake in Apple Inc (NASDAQ: 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.